Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...